Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMC2012
- Development stage
- Phase 2
- Modality
- Cell Therapies
- Administration
- Surgical Implantation
01
Overview
BMC2012 is an autologous bone marrow cell-based therapy developed for the treatment of proximal humerus fractures. It consists of preoperatively isolated autologous bone marrow cells (BMCs) seeded onto β-TCP (beta-tricalcium phosphate) in combination with angle stable fixation (Philos plate®). The therapy was tested in a clinical phase-I trial to evaluate its safety and feasibility.
Beyond the preview
Go deeper on BMC2012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMC2012.